The National Pharmaceutical Pricing Authority (NPPA) has notified the retail prices of 71 formulations as per the provisions to set prices of new drugs under the Drugs Prices Control Order (DPCO), ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Abstract —Trastuzumab, a monoclonal antibody against the HER2 receptor, was recently approved for the treatment of metastatic breast cancer. However, 28% of patients receiving both an anthracycline ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Adrienne Waks, MD, on Subcutaneous vs IV Trastuzumab/Pertuzumab in Breast Cancer – Reduced 'time toxicity' for patients ...

This study sought to estimate the difference in time burden between IV and SC administration of trastuzumab and pertuzumab (HP). Methods ...

Patients with unresectable locally advanced or metastatic HER2+ breast cancer were randomly assigned to receive trastuzumab duocarmazine or a physician’s choice.

Trastuzumab biosimilars have similar safety profiles as the originator product when used to treat early or metastatic HER2-positive breast cancer.